StockData
Alaunos Therapeutics, Inc. logo

Alaunos Therapeutics, Inc. (TCRT) income statement

TCRTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 4/30
$1.66+0.07 (+4.40%)

Close on Nov 20, 2026Market cap $4.22MP/E –Yield –

Alaunos Therapeutics, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
–
Operating margin
-135266.7%
Net margin
-133666.7%
Return on equity, FY2025
-198.1%

Financial strength

Current ratio
0.77
Debt to equity
–
Debt to assets
–
Cash to current liabilities
14.4%

Valuation

P/E ratio
–
Price to sales
1405.73
Price to book
6.47
Dividend yield
–

See a number that looks wrong?